Alzamend Neuro, Inc. (ALZN) 10-Year Financial Performance & Capital Metrics

ALZN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Show more

Revenue $0
EBITDA -$4M +55.0%
Net Income -$5M +54.6%
EPS (Diluted) -11.32 +23.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -657.17% +85.1%
ROIC -
Debt/Equity -
Interest Coverage -249.42 +74.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 86.7% through buybacks
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM40.09%

ROCE

10Y Avg-8783.89%

5Y Avg-1149.93%

3Y Avg-1746.64%

Latest-654.54%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	50.74K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	-23.07K	-50.74K	-50.74K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-1.2%	0%
Operating Expenses+	69.46K	1.55M	898.43K	5.01M	4.42M	4.95M	12.32M	14.87M	9.94M	4.45M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	69.46K	1.27M	575.03K	1.31M	3.35M	3.64M	7.12M	7.42M	3.48M	3.03M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	275.05K	323.4K	3.7M	1.07M	1.31M	5.2M	7.45M	6.46M	1.41M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-69.46K	-1.55M	-898K	-5.01M	-4.42M	-4.95M	-12.32M	-14.87M	-9.94M	-4.5M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-21.29%	0.42%	-4.58%	0.12%	-0.12%	-1.49%	-0.21%	0.33%	0.55%
EBITDA+	0	0	430	0	0	0	-12.32M	-14.85M	-9.89M	-4.45M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-1%	-	-	-	-0.21%	0.33%	0.55%
D&A (Non-Cash Add-back)	69.46K	1.55M	898.43K	5.01M	4.42M	4.95M	3.55K	23.07K	50.74K	50.74K
EBIT	-69.46K	-1.55M	-891K	-4.86M	-4.41M	-4.89M	-12.32M	-14.87M	-9.94M	-4.5M
Net Interest Income+	0	0	0	0	13.93K	-157K	-46.48K	-7.69K	-10.1K	-18.03K
Interest Income	0	21.5K	33.23K	146.39K	13.93K	1.71K	47	8	0	0
Interest Expense	0	0	0	0	0	158.8K	46.52K	7.7K	10.1K	18.03K
Other Income/Expense	0	-21.5K	-33.23K	146.39K	13.93K	-94.68K	-42.52K	-7.7K	-10.1K	-18.03K
Pretax Income+	-69.46K	-1.57M	-932K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-69.46K	-1.57M	-932K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-21.6%	0.41%	-4.22%	0.09%	-0.14%	-1.45%	-0.2%	0.33%	0.55%
Net Income (Continuing)	-69.46K	-1.57M	-932K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.42	-8.18	-1.64	-12.40	-9.25	-0.89	-2.10	-2.25	-14.70	-11.32
EPS Growth %	-	-18.48%	0.8%	-6.56%	0.25%	0.9%	-1.36%	-0.07%	-5.53%	0.23%
EPS (Basic)	-0.42	-8.18	-1.64	-12.40	-9.26	-0.89	-20.92	-2.25	-14.72	-11.32
Diluted Shares Outstanding	826.49K	960.04K	2.84M	1.96M	2.38M	2.42M	2.97M	3.25M	3.38M	450.8K
Basic Shares Outstanding	825K	960K	2.84M	1.96M	2.38M	2.42M	2.96M	3.25M	3.38M	450.8K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Total Current Assets+	5.61K	57.29K	2.42M	1.5M	1.81M	2.91M	14.41M	5.84M	455.24K	4.18M
Cash & Short-Term Investments	1.14K	4.98K	545K	42.61K	90.28K	1.93M	14.06M	5.14M	376.05K	3.95M
Cash Only	1.14K	4.98K	545K	42.61K	90.28K	1.93M	14.06M	5.14M	376.05K	3.95M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	424.35K	285.35K	194.28K	16.21K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	-16.21K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	3.54K	1.7K	0	0	0	0	0	0	0	0
Total Non-Current Assets+	25K	75K	0	0	0	352.5K	102.91K	79.84K	176.35K	425.61K
Property, Plant & Equipment	0	0	0	0	0	0	102.91K	79.84K	176.35K	425.61K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	25K	75K	0	0	0	352.5K	0	0	0	0
Total Assets+	30.61K	132.29K	2.42M	1.5M	1.81M	2.91M	14.52M	5.92M	631.59K	4.6M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	3.32%	17.26%	-0.38%	0.21%	0.61%	3.98%	-0.59%	-0.89%	6.29%
Total Current Liabilities+	30.72K	717.22K	96.72K	1.18M	992.31K	899.64K	1.16M	2.87M	3.23M	634.76K
Accounts Payable	2.6K	125.97K	90.09K	1.1M	929.64K	503.59K	1.16M	2.87M	2.93M	634.76K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	4.57K
Short-Term Debt	3.12K	591.26K	0	79	63	335.3K	0	0	300.71K	0
Deferred Revenue (Current)	0	0	0	-79	-63	0	0	0	0	0
Other Current Liabilities	25K	0	0	-79	-63	0	0	0	0	0
Current Ratio	0.18x	0.08x	24.98x	1.27x	1.83x	3.24x	12.37x	2.03x	0.14x	6.58x
Quick Ratio	0.18x	0.08x	24.98x	1.27x	1.83x	3.26x	12.37x	2.03x	0.14x	6.58x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.1M	0	0	1.16M	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	30.72K	717.22K	96.72K	1.18M	992.31K	899.64K	1.16M	2.87M	3.23M	634.76K
Total Debt+	3.12K	591.26K	0	79	63	335.3K	0	0	300.71K	0
Net Debt	1.98K	586.28K	-545K	-42.53K	-90.22K	-1.59M	-14.06M	-5.14M	-75.33K	-3.95M
Debt / Equity	-	-	-	0.00x	0.00x	0.17x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-1267.44x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-31.18x	-264.81x	-1930.92x	-983.86x	-249.42x
Total Equity+	-106	-584.93K	2.32M	316.92K	821.71K	2.01M	13.35M	3.05M	-2.59M	3.97M
Equity Growth %	-	-5517.21%	4.97%	-0.86%	1.59%	1.45%	5.63%	-0.77%	-1.85%	2.53%
Book Value per Share	-0.00	-0.61	0.82	0.16	0.35	0.83	4.50	0.94	-0.77	8.80
Total Shareholders' Equity	-106	-584.93K	2.32M	316.92K	821.71K	2.01M	13.35M	3.05M	-2.59M	3.97M
Common Stock	4.64K	3.29K	4.95K	6.19K	6.48K	6.74K	9.55K	9.69K	69	78
Retained Earnings	-11.58K	-1.58M	-2.51M	-7.38M	-11.79M	-16.83M	-29.19M	-44.07M	-54.02M	-58.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3K	0	-4.95K	-15M	-14.98M	-14.88M	-14.88M	-14.88M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Cash from Operations+	-18.49K	-1.42M	-2.05M	-1.05M	-2.35M	-2.71M	-6.61M	-8.92M	-8.27M	-6.57M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-75.61%	-0.45%	0.49%	-1.24%	-0.16%	-1.44%	-0.35%	0.07%	0.21%
Net Income	-69.46K	-1.57M	-931.66K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Depreciation & Amortization	0	0	0	0	0	0	3.55K	23.07K	50.74K	50.74K
Stock-Based Compensation	40.98K	114.41K	218.42K	396.17K	1.8M	2.03M	4.41M	3.58M	955.63K	325.11K
Deferred Taxes	0	0	0	0	0	0	0	-1.71M	0	0
Other Non-Cash Items	15.61K	88.47K	227.21K	2.19M	562.28K	454.63K	8.77K	1.71M	714	9.29K
Working Capital Changes	-5.63K	-49.68K	-1.35M	1.23M	-299.35K	-152.45K	1.33M	2.35M	670.67K	-2.44M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	693.58K	1.71M	0	0
Cash from Investing+	0	0	-400K	234.09K	105K	100.92K	-106.46K	0	-147.24K	-300K
Capital Expenditures	0	0	0	0	0	0	-106.46K	0	-147.24K	-300K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-400K	234.09K	105K	100.92K	-5.37M	0	0	0
Cash from Financing+	25.34K	1.42M	2.99M	308.72K	2.29M	4.45M	18.85M	200	3.65M	10.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	25.34K	1.42M	-259.41K	72.7K	2.29M	4.05M	18.85M	200	0	600
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.49K	-1.42M	-2.05M	-1.05M	-2.35M	-2.71M	-6.72M	-8.92M	-8.42M	-6.87M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-75.61%	-0.45%	0.49%	-1.24%	-0.16%	-1.48%	-0.33%	0.06%	0.18%
FCF per Share	-0.02	-1.48	-0.72	-0.53	-0.99	-1.12	-2.26	-2.74	-2.49	-15.24
FCF Conversion (FCF/Net Income)	0.27x	0.90x	2.20x	0.21x	0.53x	0.54x	0.54x	0.60x	0.83x	1.45x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-107.47%	-368.86%	-774.62%	-356.09%	-160.92%	-181.47%	-4408.42%	-657.17%
Return on Invested Capital (ROIC)	-	-72044.68%	-75.86%	-366.75%	-659.72%	-645.65%	-	-	-	-
Debt / Equity	-	-	-	0.00x	0.00x	0.17x	-	-	-	-
Interest Coverage	-	-	-	-	-	-31.18x	-264.81x	-1930.92x	-983.86x	-249.42x
FCF Conversion	0.27x	0.90x	2.20x	0.21x	0.53x	0.54x	0.54x	0.60x	0.83x	1.45x

Frequently Asked Questions

Growth & Financials

Alzamend Neuro, Inc. (ALZN) grew revenue by 0.0% over the past year. Growth has been modest.

Alzamend Neuro, Inc. (ALZN) reported a net loss of $5.9M for fiscal year 2025.

Dividend & Returns

Alzamend Neuro, Inc. (ALZN) has a return on equity (ROE) of -657.2%. Negative ROE indicates the company is unprofitable.

Alzamend Neuro, Inc. (ALZN) had negative free cash flow of $5.9M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Alzamend Neuro, Inc. (ALZN) 10-Year Financial Performance & Capital Metrics

ALZN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0
EBITDA -$4M +55.0%
Net Income -$5M +54.6%
EPS (Diluted) -11.32 +23.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -657.17% +85.1%
ROIC -
Debt/Equity -
Interest Coverage -249.42 +74.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 86.7% through buybacks
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM40.09%

ROCE

10Y Avg-8783.89%

5Y Avg-1149.93%

3Y Avg-1746.64%

Latest-654.54%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	50.74K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	-23.07K	-50.74K	-50.74K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-1.2%	0%
Operating Expenses+	69.46K	1.55M	898.43K	5.01M	4.42M	4.95M	12.32M	14.87M	9.94M	4.45M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	69.46K	1.27M	575.03K	1.31M	3.35M	3.64M	7.12M	7.42M	3.48M	3.03M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	275.05K	323.4K	3.7M	1.07M	1.31M	5.2M	7.45M	6.46M	1.41M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-69.46K	-1.55M	-898K	-5.01M	-4.42M	-4.95M	-12.32M	-14.87M	-9.94M	-4.5M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-21.29%	0.42%	-4.58%	0.12%	-0.12%	-1.49%	-0.21%	0.33%	0.55%
EBITDA+	0	0	430	0	0	0	-12.32M	-14.85M	-9.89M	-4.45M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-1%	-	-	-	-0.21%	0.33%	0.55%
D&A (Non-Cash Add-back)	69.46K	1.55M	898.43K	5.01M	4.42M	4.95M	3.55K	23.07K	50.74K	50.74K
EBIT	-69.46K	-1.55M	-891K	-4.86M	-4.41M	-4.89M	-12.32M	-14.87M	-9.94M	-4.5M
Net Interest Income+	0	0	0	0	13.93K	-157K	-46.48K	-7.69K	-10.1K	-18.03K
Interest Income	0	21.5K	33.23K	146.39K	13.93K	1.71K	47	8	0	0
Interest Expense	0	0	0	0	0	158.8K	46.52K	7.7K	10.1K	18.03K
Other Income/Expense	0	-21.5K	-33.23K	146.39K	13.93K	-94.68K	-42.52K	-7.7K	-10.1K	-18.03K
Pretax Income+	-69.46K	-1.57M	-932K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-69.46K	-1.57M	-932K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-21.6%	0.41%	-4.22%	0.09%	-0.14%	-1.45%	-0.2%	0.33%	0.55%
Net Income (Continuing)	-69.46K	-1.57M	-932K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.42	-8.18	-1.64	-12.40	-9.25	-0.89	-2.10	-2.25	-14.70	-11.32
EPS Growth %	-	-18.48%	0.8%	-6.56%	0.25%	0.9%	-1.36%	-0.07%	-5.53%	0.23%
EPS (Basic)	-0.42	-8.18	-1.64	-12.40	-9.26	-0.89	-20.92	-2.25	-14.72	-11.32
Diluted Shares Outstanding	826.49K	960.04K	2.84M	1.96M	2.38M	2.42M	2.97M	3.25M	3.38M	450.8K
Basic Shares Outstanding	825K	960K	2.84M	1.96M	2.38M	2.42M	2.96M	3.25M	3.38M	450.8K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Total Current Assets+	5.61K	57.29K	2.42M	1.5M	1.81M	2.91M	14.41M	5.84M	455.24K	4.18M
Cash & Short-Term Investments	1.14K	4.98K	545K	42.61K	90.28K	1.93M	14.06M	5.14M	376.05K	3.95M
Cash Only	1.14K	4.98K	545K	42.61K	90.28K	1.93M	14.06M	5.14M	376.05K	3.95M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	424.35K	285.35K	194.28K	16.21K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	-16.21K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	3.54K	1.7K	0	0	0	0	0	0	0	0
Total Non-Current Assets+	25K	75K	0	0	0	352.5K	102.91K	79.84K	176.35K	425.61K
Property, Plant & Equipment	0	0	0	0	0	0	102.91K	79.84K	176.35K	425.61K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	25K	75K	0	0	0	352.5K	0	0	0	0
Total Assets+	30.61K	132.29K	2.42M	1.5M	1.81M	2.91M	14.52M	5.92M	631.59K	4.6M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	3.32%	17.26%	-0.38%	0.21%	0.61%	3.98%	-0.59%	-0.89%	6.29%
Total Current Liabilities+	30.72K	717.22K	96.72K	1.18M	992.31K	899.64K	1.16M	2.87M	3.23M	634.76K
Accounts Payable	2.6K	125.97K	90.09K	1.1M	929.64K	503.59K	1.16M	2.87M	2.93M	634.76K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	4.57K
Short-Term Debt	3.12K	591.26K	0	79	63	335.3K	0	0	300.71K	0
Deferred Revenue (Current)	0	0	0	-79	-63	0	0	0	0	0
Other Current Liabilities	25K	0	0	-79	-63	0	0	0	0	0
Current Ratio	0.18x	0.08x	24.98x	1.27x	1.83x	3.24x	12.37x	2.03x	0.14x	6.58x
Quick Ratio	0.18x	0.08x	24.98x	1.27x	1.83x	3.26x	12.37x	2.03x	0.14x	6.58x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.1M	0	0	1.16M	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	30.72K	717.22K	96.72K	1.18M	992.31K	899.64K	1.16M	2.87M	3.23M	634.76K
Total Debt+	3.12K	591.26K	0	79	63	335.3K	0	0	300.71K	0
Net Debt	1.98K	586.28K	-545K	-42.53K	-90.22K	-1.59M	-14.06M	-5.14M	-75.33K	-3.95M
Debt / Equity	-	-	-	0.00x	0.00x	0.17x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-1267.44x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-31.18x	-264.81x	-1930.92x	-983.86x	-249.42x
Total Equity+	-106	-584.93K	2.32M	316.92K	821.71K	2.01M	13.35M	3.05M	-2.59M	3.97M
Equity Growth %	-	-5517.21%	4.97%	-0.86%	1.59%	1.45%	5.63%	-0.77%	-1.85%	2.53%
Book Value per Share	-0.00	-0.61	0.82	0.16	0.35	0.83	4.50	0.94	-0.77	8.80
Total Shareholders' Equity	-106	-584.93K	2.32M	316.92K	821.71K	2.01M	13.35M	3.05M	-2.59M	3.97M
Common Stock	4.64K	3.29K	4.95K	6.19K	6.48K	6.74K	9.55K	9.69K	69	78
Retained Earnings	-11.58K	-1.58M	-2.51M	-7.38M	-11.79M	-16.83M	-29.19M	-44.07M	-54.02M	-58.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3K	0	-4.95K	-15M	-14.98M	-14.88M	-14.88M	-14.88M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Cash from Operations+	-18.49K	-1.42M	-2.05M	-1.05M	-2.35M	-2.71M	-6.61M	-8.92M	-8.27M	-6.57M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-75.61%	-0.45%	0.49%	-1.24%	-0.16%	-1.44%	-0.35%	0.07%	0.21%
Net Income	-69.46K	-1.57M	-931.66K	-4.86M	-4.41M	-5.05M	-12.36M	-14.88M	-9.95M	-4.51M
Depreciation & Amortization	0	0	0	0	0	0	3.55K	23.07K	50.74K	50.74K
Stock-Based Compensation	40.98K	114.41K	218.42K	396.17K	1.8M	2.03M	4.41M	3.58M	955.63K	325.11K
Deferred Taxes	0	0	0	0	0	0	0	-1.71M	0	0
Other Non-Cash Items	15.61K	88.47K	227.21K	2.19M	562.28K	454.63K	8.77K	1.71M	714	9.29K
Working Capital Changes	-5.63K	-49.68K	-1.35M	1.23M	-299.35K	-152.45K	1.33M	2.35M	670.67K	-2.44M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	693.58K	1.71M	0	0
Cash from Investing+	0	0	-400K	234.09K	105K	100.92K	-106.46K	0	-147.24K	-300K
Capital Expenditures	0	0	0	0	0	0	-106.46K	0	-147.24K	-300K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-400K	234.09K	105K	100.92K	-5.37M	0	0	0
Cash from Financing+	25.34K	1.42M	2.99M	308.72K	2.29M	4.45M	18.85M	200	3.65M	10.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	25.34K	1.42M	-259.41K	72.7K	2.29M	4.05M	18.85M	200	0	600
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.49K	-1.42M	-2.05M	-1.05M	-2.35M	-2.71M	-6.72M	-8.92M	-8.42M	-6.87M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-75.61%	-0.45%	0.49%	-1.24%	-0.16%	-1.48%	-0.33%	0.06%	0.18%
FCF per Share	-0.02	-1.48	-0.72	-0.53	-0.99	-1.12	-2.26	-2.74	-2.49	-15.24
FCF Conversion (FCF/Net Income)	0.27x	0.90x	2.20x	0.21x	0.53x	0.54x	0.54x	0.60x	0.83x	1.45x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-107.47%	-368.86%	-774.62%	-356.09%	-160.92%	-181.47%	-4408.42%	-657.17%
Return on Invested Capital (ROIC)	-	-72044.68%	-75.86%	-366.75%	-659.72%	-645.65%	-	-	-	-
Debt / Equity	-	-	-	0.00x	0.00x	0.17x	-	-	-	-
Interest Coverage	-	-	-	-	-	-31.18x	-264.81x	-1930.92x	-983.86x	-249.42x
FCF Conversion	0.27x	0.90x	2.20x	0.21x	0.53x	0.54x	0.54x	0.60x	0.83x	1.45x

Frequently Asked Questions

Growth & Financials

Alzamend Neuro, Inc. (ALZN) grew revenue by 0.0% over the past year. Growth has been modest.

Alzamend Neuro, Inc. (ALZN) reported a net loss of $5.9M for fiscal year 2025.

Dividend & Returns

Alzamend Neuro, Inc. (ALZN) has a return on equity (ROE) of -657.2%. Negative ROE indicates the company is unprofitable.

Alzamend Neuro, Inc. (ALZN) had negative free cash flow of $5.9M in fiscal year 2025, likely due to heavy capital investments.